Search - tctmd.com

Displaying 1 - 20 of 89

Sort: Relevancy | Date

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

April 12, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

March 09, 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

March 04, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

What’s Going to Be Hot at ACC/WCC 2023?

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

February 27, 2023

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

April 06, 2022

In Vaccine Era, Deaths Drop Sharply in STEMI Patients With COVID-19

News Conference News ACC 2022

In Vaccine Era, Deaths Drop Sharply in STEMI Patients With COVID-19

April 04, 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

April 02, 2022

Pericardial Effusion Signals Worse Prognosis in COVID-19 Inpatients

News Conference News ACC 2022

Pericardial Effusion Signals Worse Prognosis in COVID-19 Inpatients

March 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.